Vertaling van "involve a structural risk with regard " (Nederlands → Frans) :

As for D-glucuronolactone, the group believes that this concerns a normal human metabolite deriving from glucose, which does not involve a structural risk with regard to mutagenicity or carcinogenicity. It also holds that both this component as well as its hydrolysis product, glucuronic acid, are endogenous metabolites in humans and other mammals, that they are naturally present in various food sources and that they are quickly metabolised into innocuous products and excreted.
Pour la D-glucuronolactone, le groupe considère qu’il s’agit d’un métabolite humain normal provenant du glucose qui ne présente pas de risque structural en termes de mutagénicité ou de carcinogénicité, que pour ce composant, comme pour son produit d’hydrolyse, l’acide glucuronique, il s’agit de métabolites endogènes chez l’homme et les autres mammifères, qu’ils se trouvent à l’état naturel dans diverses sources alimentaires et qu’ils sont rapidement métabolisés en produits sans danger et excrétés.

This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines.
DISCLOSURE NOTICE: The information contained in this release is as of December 12, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

At the level of those involved the risk factors that need to be taken into consideration are those regarding the research sites themselves.
At the level of those involved the risk factors that need to be taken into consideration are those regarding the research sites themselves.

As regards schizophrenia, the risk of suicide is greater with male patients in the first stages of the disorder, especially with patients who were particularly dynamic before the disorder started, and with patients who suffer chronic relapses.
En ce qui concerne la schizophrénie, le risque de suicide est plus marqué chez les patients masculins, dans les premiers stades de la maladie, en particulier auprès des patients particulièrement dynamiques avant la déclaration de la maladie, et auprès des patients avec des rechutes chroniques.

Together with the WVVH, it was involved in the Delfi study, which aims to record the weak points in the co-operation of various forms of health care provided to patients with a suicide risk.
Avec la WVVH, il a collaboré à l’étude Delfi qui veut faire un bilan des points faibles dans la collaboration des différentes lignes de soins de santé au niveau des patients présentant un risque suicidaire.

medicinal products with regard to vCJD risk», November 2003, EMEA/CPMP/BWP/5136/03. c) CHMP Position Statement «Creutzfeldt-Jakob disease and plasma-derived and urine-derived
Derived Medicinal Products with regard to vCJD risk», October 2004, EMEA/CPMP/BWP/5136/03.

There is a risk that dealing with access to means might only affect the external causes involved in committing the act, without taking into account the other factors.
Des actions au niveau de l’accessibilité aux moyens risquent de n’agir que sur les causes externes de passage à l’acte sans prendre en compte les autres facteurs.